健脾益肾方对非小细胞肺癌细胞体外增殖凋亡作用的实验研究

目的:探讨健脾益肾方对非小细胞肺癌(NSCLC)细胞体外增殖凋亡的作用。方法:人NSCLC细胞系A549分为四组:空白对照组(仅加入细胞培养液)、阴性对照组(加入细胞,不进行中药处理)、实验组(加细胞加中药处理)。荧光定量PCR和Western blot分别检测Survivin、Bcl-2和Caspase-3的mRNA和蛋白表达。MTT检测细胞增殖;流式细胞术检测细胞凋亡。结果:与空白对照组相比,阴性对照组细胞在24、48、72 h的吸光度值明显升高,细胞凋亡率下降,Survivin和Bcl-2 mRNA和蛋白相对表达量上调,Caspase-3 mRNA和蛋白相对表达量下调,组间比较差异有统计学意义(P<0.05);而健脾益肾方处理的实验组24、48、72 h的吸光度值均显著降低,细胞凋亡率显著上升,Survivin和Bcl-2 mRNA和蛋白相对表达量下调,Caspase-3 mRNA和蛋白相对表达量上调,与空白对照组相比差异有统计学意义(P<0.05)。结论:健脾益肾方可通过下调Survivin和Bcl-2、上调Caspase-3表达诱导NSCLC细胞凋亡,并抑制肿瘤细胞的增殖,进而抑制NSCLC的发展。     

The interaction between pain and movement

Study DesignClinical commentary.Introduction/PurposePain and movement are universally relevant phenomena that influence human experiences in readily observable ways. Improved understanding of pain-movement relationships can guide medical and rehabilitative approaches to recovery and decrease risk of dysfunctional long-term consequences of otherwise normal neuromuscular responses. Therefore, the overall intent of this article is to elucidate the relationships between pain and movement as they relate to clinical decision making.ConclusionsMotor output is highly adaptable, can be influenced by multiple mechanisms at various levels along the nervous system, and may vary between individuals despite similar diagnoses. Therefore, interventions need to be individualized and consider both the types of motor response observed (ie, whether the response is protective or maladaptive), and the patient's acute physical activity tolerance when prescribing exercise/movement.     

Are primary care physicians ill equipped to evaluate and treat childhood physical inactivity?

ABSTRACT

Objective

To investigate primary care physician clinical practice patterns, barriers, and education surrounding pediatric physical activity (PA), and to compare practice patterns by discipline.     

再谈辛味药在方剂中的作用

气味理论是中药药性理论的核心内容。五味中之辛味能兼通四气,复兼四味。历代医籍有关气味配伍的记载有很多。如辛行淡渗、辛甘化阳、辛散咸软、辛散酸收、辛开苦降等配伍方法,充分体现了辛味药物在方剂配伍应用中的广泛性特点。因此,认真研究、总结辛味药在方剂中的作用并进而探讨其配伍规律,具有重要的理论意义和应用价值。本文以辛味药为例,探讨其在方剂学中的作用,发现:辛味药的作用主要体现在"运动"二字。这与中医学对机体的认识的主旨思想"阴阳相贯,如环无端"相一致。作用机理在于:以其"动"的特性,协其他药性之偏以纠正机体阴阳之偏,即以偏纠偏。     

壮医龙盘止咳方治疗小儿急性支气管炎风热犯肺证30例临床观察

目的:观察壮医龙盘止咳方治疗小儿急性支气管炎风热犯肺证的临床疗效。方法:选取60例急性支气管炎风热犯肺证的患儿,将其随机分为2组,每组各30例。治疗组采用壮医龙盘止咳方治疗,对照组予小儿宣肺止咳颗粒治疗,治疗5d后观察2组患儿的疗效、白介素-4(IL-4)和干扰素-γ(INF-γ)含量的变化情况,并进行中医证候评分。结果:总有效率治疗组为89.66%(26/29),对照组为76.67%(23/30),2组比较,差异有统计学意义(P<0.05);治疗组治疗后IL-4高于对照组,INF-γ及中医证候积分均低于对照组,各项指标组间比较,差异均有统计学意义(P<0.05)。结论:壮医龙盘止咳方治疗小儿急性支气管炎风热犯肺证疗效显著,值得推广应用。     

愈骨疗伤片的处方筛选及制备工艺研究

  目的：优化愈骨疗伤片的制备工艺,筛选最优制剂处方。  方法：在考察提取物粒径基础上,以片剂中川续断皂苷溶出量作为考察指标,采用正交试验对搅拌速度、制粒速度和聚维酮K30浆液浓度三者关系进一步考察。采用单因素进一步优选润滑剂和包衣工艺条件。  结果：最佳的愈骨疗伤片处方为提取物颗粒中加入10%乳糖、7.5%羧甲基淀粉钠和2.5%聚维酮K30,以及0.5%硬脂酸镁混合后压片；采用低浓度乙醇包衣液进行包衣。  结论：制得的愈骨疗伤片制剂工艺稳定,包衣后改善了片剂的吸潮性,增加了产品的稳定性,更便于保存和运输。     

经典名方泽泻汤的HPLC指纹图谱及多指标含量测定研究

目的建立经典名方泽泻汤的HPLC指纹图谱,结合化学模式识别技术对其进行分析,并测定泽泻汤中3种成分23-乙酰泽泻醇B、23-乙酰泽泻醇C和白术内酯Ⅲ的含量,为泽泻汤质量控制提供科学依据。方法采用Waters WAT054275C18色谱柱(250 mm×4.6 mm,5μm),以乙腈-水为流动相进行梯度洗脱,建立15批泽泻汤的HPLC指纹图谱,并采用"中药色谱指纹图谱相似度评价系统"、SPSS22.0及SIMCA14.1软件对15批泽泻汤的HPLC指纹图谱进行相似度评价及聚类分析(CA)、偏最小二乘判别分析(PLS-DA)等化学模式识别。同时测定23-乙酰泽泻醇B、23-乙酰泽泻醇C和白术内酯Ⅲ的含量。结果建立了15批泽泻汤的HPLC指纹图谱,相似度均0.94,标定了18个共有峰,指认出3个色谱峰,分别为11号峰白术内酯Ⅲ、15号峰23-乙酰泽泻醇C、16号峰23-乙酰泽泻醇B,CA和PLS-DA将15批泽泻汤样品分为2类,同时15批泽泻汤中23-乙酰泽泻醇B、23-乙酰泽泻醇C和白术内酯Ⅲ的质量分数分别为0.321～0.569、0.075～0.139、0.106～0.142 mg/g。结论 HPLC指纹图谱结合多成分同时测定的方法,快速、简便、重复性好,为泽泻汤及其制剂的质量评价提供参考。     

补肾利水方联合玻璃体腔注射雷珠单抗治疗湿性年龄相关性黄斑变性临床研究

目的:观察补肾利水方联合玻璃体腔注射雷珠单抗治疗湿性年龄相关性黄斑变性(AMD)的临床疗效。方法:选取60例湿性AMD患者,按照随机数字表法分为治疗组和对照组,每组30例(眼数30只)。治疗组给予补肾利水方联合玻璃体腔注射雷珠单抗治疗,对照组单纯给予玻璃体腔注射雷珠单抗治疗。观察2组治疗前后最佳矫正视力、黄斑中心凹视网膜厚度和中医证候积分的变化。结果:治疗后,2组最佳矫正视力均较治疗前提高(P<0.05)。治疗组治疗3个月后最佳矫正视力优于对照组(P<0.05)。治疗后,2组黄斑中心凹视网膜厚度均较治疗前缩小(P<0.05);治疗组治疗3个月后黄斑中心凹视网膜厚度小于对照组(P<0.05)。治疗3个月后,2组各项中医证候积分均较治疗前降低(P<0.05),治疗组视物昏朦、视物变形、腰膝无力积分均比对照组降低更明显(P<0.05)。结论:补肾利水方联合玻璃体腔注射雷珠单抗治疗湿性AMD,可以提高患者的视力,缩小黄斑中心凹视网膜厚度,改善中医证候,疗效优于单纯玻璃体腔注射雷珠单抗治疗。     

Preference for brand-name buprenorphine is related to severity of addiction among outpatients in opioid maintenance treatment

As a form of opioid maintenance treatment, high-dose buprenorphine is increasingly being used in the United States. On the French market since 1996, it is the most commonly prescribed and frequently employed opioid maintenance treatment. For unknown reasons, the brand-name form is used far more often than the generic form (76–24%). The objective was to show that the patients' levels of addiction were differentiated according to the form of buprenorphine currently being used and to their previous experience of a different form. An observational study in 9 sites throughout France used self-assessment questionnaires filled out in retail pharmacies by all patients to whom their prescribed buprenorphine treatment was being delivered. The 151 canvassed pharmacies solicited 879 patients, of whom 724 completed the questionnaires. Participants were statistically similar to non-participants. The patients using the brand-name form subsequent to experience with the generic form exhibited a more elevated addiction severity index and a higher dosage than brand-name form users with no experience of a different form. Compared to generic users, their doses were higher, their was addiction more severe, and their alcohol consumption was more excessive; they were also more likely to make daily use of psychotropic substances. However, the level of misuse or illicit consumption was similar between these groups. Preferring the brand-name buprenorphine form to the generic form is associated with a higher level of severe addiction, a more frequent need for daily psychotropics, and excessive drinking; but the study was unable to show a causal link.